Prostate-specific antigen testing in Tyrol, Austria: Prostate cancer mortality reduction was supported by an update with mortality data up to 2008 - Abstract

Cancer Registry of Tyrol, TILAK GmbH, Anichstrasse 35, Innsbruck, Austria.


The objective of this study was to update an in-depth analysis of the time trend for prostate cancer (PCA) mortality in the population of Tyrol by 5 years, namely to 2008. In Tyrol, prostate-specific antigen (PSA) tests were introduced in 1988/89; more than three-quarters of all men in the age group 45-74 had at least one PSA test in the past decade.

We applied the same model as in a previous publication, i.e., an age-period-cohort model using Poisson regression, to the mortality data covering more than three decades from 1970 to 2008.

For Tyrol from 2004 to 2008 in the age group 60+ period terms show a significant reduction in prostate cancer mortality with a risk ratio of 0.70 (95% confidence interval 0.57, 0.87) for Tyrol, and for Austria excluding Tyrol a moderate reduction with a risk ratio of 0.92 (95% confidence interval 0.87, 0.97), each compared to the mortality rate in the period 1989-1993.

This update strengthens our previously published results, namely that PSA testing offered to a population at no charge can reduce prostate cancer mortality. The extent of mortality reduction is in line with that reported in the other recent publications. However, our data do not permit us to fully assess the harms associated with PCA screening, and no recommendation for PSA screening can be made without a careful evaluation of overdiagnosis and overtreatment.

Written by:
Oberaigner W, Siebert U, Horninger W, Klocker H, Bektic J, Schäfer G, Frauscher F, Schennach H, Bartsch G.   Are you the author?

Reference: Int J Public Health. 2011 Jun 17. Epub ahead of print.
doi: 10.1007/s00038-011-0266-4

PubMed Abstract
PMID: 21681451 Prostate Cancer Section